Daniel Geller1, Craig Donnelly2, Frank Lopez2, Richard Rubin2, Jeffrey Newcorn2, Virginia Sutton2, Rosalie Bakken2, Martin Paczkowski2, Douglas Kelsey2, Calvin Sumner2. 1. Dr. Geller is with the Pediatric Psychopharmacology Research Program, Massachusetts General Hospital, Cambridge; Dr. Donnelly is with the Department of Psychiatry, Dartmouth Hitchcock Medical Center, Lebanon, NH; Dr. Lopez is with Children's Developmental C enter, Maitland, FL; Dr. Rubin is with University of Vermont College of Medicine, Burlington; Dr. Newcorn is with the Department of Psychiatry, Mount Sinai School of Medicine, New York; Drs. Sutton, Bakken, Kelsey, and Sumner and Mr. Paczkowski are with the Lilly Research Laboratories, Indianapolis.. Electronic address: dageller@partners.org. 2. Dr. Geller is with the Pediatric Psychopharmacology Research Program, Massachusetts General Hospital, Cambridge; Dr. Donnelly is with the Department of Psychiatry, Dartmouth Hitchcock Medical Center, Lebanon, NH; Dr. Lopez is with Children's Developmental C enter, Maitland, FL; Dr. Rubin is with University of Vermont College of Medicine, Burlington; Dr. Newcorn is with the Department of Psychiatry, Mount Sinai School of Medicine, New York; Drs. Sutton, Bakken, Kelsey, and Sumner and Mr. Paczkowski are with the Lilly Research Laboratories, Indianapolis.
Abstract
OBJECTIVE: Research suggests 25% to 35% of children with attention-deficit/hyperactivity disorder (ADHD) have comorbid anxiety disorders. This double-blind study compared atomoxetine with placebo for treating pediatric ADHD with comorbid anxiety, as measured by the ADHD Rating Scale-IV-Parent Version: Investigator Administered and Scored (ADHDRS-IV-PI) and the Pediatric Anxiety Rating Scale (PARS). METHOD: Patients (ages 8-17 years) meeting DSM-IV criteria for ADHD and generalized anxiety disorder, separation anxiety disorder, and/orsocial phobia were randomized to 12 weeks of atomoxetine (n = 87) or placebo (n = 89). ADHDRS-IV-PI and PARS total scores were analyzed using analysis of covariance last observation carried forward and repeated-measures analyses. RESULTS:Sixty-six patients in each group completed the study. Mean ADHDRS-IV-PI total score improved significantly for atomoxetine (n = 55; -10.5, SD 10.6) relative to placebo (n = 58; -1.4, SD 8.3; p < .001). Mean PARS total score also improved significantly for atomoxetine (n = 55; -5.5, SD 4.8) relative to placebo (n = 58; -3.2, SD 5.0; p = .011). CONCLUSIONS:Atomoxetine was efficacious in reducing ADHD symptoms in patients who have ADHD with comorbid anxiety and was well tolerated. There was also a significant reduction in independently assessed anxiety symptoms using both clinician-rated and self-rated measures, which merits further investigation. Results support consideration of atomoxetine for the treatment of ADHD in youths who have ADHD with comorbid anxiety disorder. CLINICAL TRIAL REGISTRATION INFORMATION: The LYBP study, on which this article is based, was not registered at clinicaltrials.gov because the last patient visit occurred before July 1, 2005. Results, however, are publicly posted at lillytrials.com and clinicalstudyresults.org. The unique study ID at both sites is 6477a.
RCT Entities:
OBJECTIVE: Research suggests 25% to 35% of children with attention-deficit/hyperactivity disorder (ADHD) have comorbid anxiety disorders. This double-blind study compared atomoxetine with placebo for treating pediatric ADHD with comorbid anxiety, as measured by the ADHD Rating Scale-IV-Parent Version: Investigator Administered and Scored (ADHDRS-IV-PI) and the Pediatric Anxiety Rating Scale (PARS). METHOD:Patients (ages 8-17 years) meeting DSM-IV criteria for ADHD and generalized anxiety disorder, separation anxiety disorder, and/or social phobia were randomized to 12 weeks of atomoxetine (n = 87) or placebo (n = 89). ADHDRS-IV-PI and PARS total scores were analyzed using analysis of covariance last observation carried forward and repeated-measures analyses. RESULTS: Sixty-six patients in each group completed the study. Mean ADHDRS-IV-PI total score improved significantly for atomoxetine (n = 55; -10.5, SD 10.6) relative to placebo (n = 58; -1.4, SD 8.3; p < .001). Mean PARS total score also improved significantly for atomoxetine (n = 55; -5.5, SD 4.8) relative to placebo (n = 58; -3.2, SD 5.0; p = .011). CONCLUSIONS:Atomoxetine was efficacious in reducing ADHD symptoms in patients who have ADHD with comorbid anxiety and was well tolerated. There was also a significant reduction in independently assessed anxiety symptoms using both clinician-rated and self-rated measures, which merits further investigation. Results support consideration of atomoxetine for the treatment of ADHD in youths who have ADHD with comorbid anxiety disorder. CLINICAL TRIAL REGISTRATION INFORMATION: The LYBP study, on which this article is based, was not registered at clinicaltrials.gov because the last patient visit occurred before July 1, 2005. Results, however, are publicly posted at lillytrials.com and clinicalstudyresults.org. The unique study ID at both sites is 6477a.
Authors: David I Appel; Bryan Brinda; John S Markowitz; Jeffrey H Newcorn; Hao-Jie Zhu Journal: Biomed Chromatogr Date: 2012-01-25 Impact factor: 1.902
Authors: Stephen P Becker; Daniel R Leopold; G Leonard Burns; Matthew A Jarrett; Joshua M Langberg; Stephen A Marshall; Keith McBurnett; Daniel A Waschbusch; Erik G Willcutt Journal: J Am Acad Child Adolesc Psychiatry Date: 2015-12-23 Impact factor: 8.829
Authors: Anna M Wehry; Katja Beesdo-Baum; Meghann M Hennelly; Sucheta D Connolly; Jeffrey R Strawn Journal: Curr Psychiatry Rep Date: 2015-07 Impact factor: 5.285
Authors: Winston Y Li; Shara E Strang; David R Brown; Re'gie Smith; Dennis L Silcox; Sheng-Gang Li; Bobby R Baldridge; K Paul Nesselroade; David C Randall Journal: Auton Neurosci Date: 2009-12-16 Impact factor: 3.145